At Abveris, we leverage decades of antibody discovery expertise to discover and deliver high-quality anti-idiotype antibodies using our DiversimAbTM platform. We apply stringent, high content screening in relevant formats predictive of downstream assay success to identify quality reagents for your specific drug development assays (e.g. PK and ADA).
We know these mAbs are critical tools for clinical assay development, and the speed with which we deliver high quality reagents ultimately impacts patients’ lives. Our team takes pride in the work we perform, and prioritizes the delivery of the highest-quality antibodies in industry leading timelines to support your clinical trials.
We like to meet in person with our Boston clients. We can setup a Zoom to connect if you're further away.